Chapter 1. Market Definition
                   
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Competitive Insights

Chapter 3. Market Dynamics
                    3.1. Drivers

                    3.2. Restraints

Chapter 4. Market Analysis
                        4.1. Porter’s Analysis
                            4.1.1. Supplier power
                            4.1.2. Buyer power
                            4.1.3. Threat of new entrant
                            4.1.4. Competitive rivalry

                        4.2. PESTEL Analysis

Chapter 5. Pricing Analysis

Chapter 6. Pipeline Analysis, By Phase

Chapter 7. Regulatory Framework
                       
Chapter 8. Market Segmentation : Market Estimates and Forecasts

                    8.1. Global Breast Cancer Drugs Market Estimates and Forecasts, by Cancer Type, Revenue (USD Million)

                    8.1.1. Hormone Receptor: Market estimates and forecasts, 2018 to 2030 (USD Million)
                    8.1.2. HER2+: Market estimates and forecasts, 2018 to 2030 (USD Million)
                    8.1.3. Triple-Negative : Market estimates and forecasts, 2018 to 2030 (USD Million)

8.2.  Global Breast Cancer Drugs Market Estimates and Forecasts, by Therapy, Revenue (USD Million)

                    8.2.1. Targeted therapy: Market estimates and forecasts, 2018 to 2030 (USD Million)

                           8.2.1.1 CDK4/6 inhibitors: Market estimates and forecasts, 2018 to 2030 (USD Million)

                           8.2.1.2 HER2-targeting agents: Market estimates and forecasts, 2018 to 2030 (USD Million)

                           8.2.1.3 mTOR inhibitor: Market estimates and forecasts, 2018 to 2030 (USD Million)

                           8.2.1.4 TROP2-targeted agents: Market estimates and forecasts, 2018 to 2030 (USD Million)

                           8.2.1.5 PI3K inhibitors: Market estimates and forecasts, 2018 to 2030 (USD Million)

                           8.2.1.6 AKT inhibitor: Market estimates and forecasts, 2018 to 2030 (USD Million)

                           8.2.1.7 PARP inhibitors: Market estimates and forecasts, 2018 to 2030 (USD Million)

                                            8.2.2. Immunotherapy: Market estimates and forecasts, 2018 to 2030 (USD Million)
                                                   8.2.2.1. PD-1 inhibitor: Market estimates and forecasts, 2018 to 2030 (USD Million)

                                            8.2.3. Hormone Therapy: Market estimates and forecasts, 2018 to 2030 (USD Million)
                                                   8.2.3.1. Selective estrogen receptor modulators (SERMs) : Market estimates and forecasts, 2018 to 2030 (USD Million)
                                                   8.2.3.2. Selective estrogen receptor degraders (SERDs): Market estimates and forecasts, 2018 to 2030 (USD Million)

                           8.2.3.3.   Aromatase inhibitors (AIs): Market estimates and forecasts, 2018 to 2030 (USD Million)

                    8.2.4.  Chemotherapy : Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape
                    9.1. Vendor market share analysis, 2024
                    9.2. Brand Analysis (Top Brands)
                    9.3. Competitive Dashboard

                    9.4 Strategy Mapping

9.4.1. New Product Launch

9.4.2. Collaborations, Mergers & Acquisitions

                     9.5 Vendor Profiles

                        9.5.1.  Merck & Co., Inc
                            9.5.1.1. Company overview
                            9.5.1.2. Financial performance
                            9.5.1.3. Product portfolio
                            9.5.1.4. Strategic initiatives

                       9.5.2. Bristol-Myers Squibb Company
                            9.5.2.1. Company overview
                            9.5.2.2. Financial performance
                            9.5.2.3. Product portfolio
                            9.5.2.4. Strategic initiatives

                        9.5.3. Genentech (ROCHE GROUP)
                            9.5.3.1. Company overview
                            9.5.3.2. Financial performance
                            9.5.3.3. Product portfolio
                            9.5.3.4. Strategic initiatives

                        9.5.4. AstraZeneca
                            9.5.4.1. Company overview
                            9.5.4.2. Financial performance
                            9.5.4.3. Product portfolio
                            9.5.4.4. Strategic initiatives

                        9.5.5. Pfizer Inc
                            9.5.5.1. Company overview
                            9.5.5.2. Financial performance
                            9.5.5.3. Product portfolio
                            9.5.5.4. Strategic initiatives

                        9.5.6. Novartis
                            9.5.6.1. Company overview
                            9.5.6.2. Financial performance
                            9.5.6.3. Product portfolio
                            9.5.6.4. Strategic initiatives

                        9.5.7. Eli Lilly and Company

                            9.5.7.1. Company overview
                            9.5.7.2. Financial performance
                            9.5.7.3. Product portfolio
                            9.5.7.4. Strategic initiatives

                        9.5.8. Gilead Sciences, Inc

                            9.5.8.1. Company overview
                            9.5.8.2. Financial performance
                            9.5.8.3. Product portfolio
                            9.5.8.4. Strategic initiatives

                        9.5.9. Puma Biotechnology, Inc
                            9.5.9.1. Company overview
                            9.5.9.2. Financial performance
                            9.5.9.3. Product portfolio
                            9.5.9.4. Strategic initiatives

                        9.5.10. MacroGenics, Inc
                            9.5.10.1. Company overview
                            9.5.10.2. Financial performance
                            8.3.14.2. Product portfolio
                            9.5.10.4. Strategic initiatives

                        9.5.10. DAIICHI SANKYO
                            9.5.10.1. Company overview
                            9.5.10.2. Financial performance
                            8.3.14.2. Product portfolio
                            9.5.10.4. Strategic initiatives

Chapter 10. Methodology and Scope

                    10.1. Research Methodology

                    10.2. Information Procurement - Sources
                        10.2.1. Secondary sources
                        10.2.2. Primary research
                        10.2.3. Details of primary research

                    10.3. Data analysis models

                    10.4. Market Formulation & Validation

                    10.5. Questionnaire

·         By Cancer Type (Hormone Receptor, HER2+, Triple-Negative) (Revenue, USD Million, 2018 - 2030)

·         By Therapy (Targeted therapy, Immunotherapy, Hormone Therapy, Chemotherapy) (Revenue, USD Million, 2018 - 2030)

1.      Genentech (ROCHE GROUP) – Herceptin, Perjeta, Phesgo, Kadcyla

2.      Pfizer Inc. – Ibrance, Tukysa

3.      Eli Lilly and Company - Verzenio

4.      Novartis – Kisqali, Piqray, Afinitor, Femara

5.      Merck & Co., Inc. – Keytruda

6.      AstraZeneca – Enhertu, Lynparza, Truqap, Faslodex, Arimidex

7.      DAIICHI SANKYO – Enhertu

8.      Gilead Sciences, Inc.– Trodelvy

9.      Puma Biotechnology, Inc.– Nerlynx

10.   MacroGenics, Inc.– Margenza

11.    Bristol-Myers Squibb Company - Abraxane